Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study › SPbU Researchers Portal

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Research output: Contribution to journal › Article › peer-review

Department of Oncology

DOI

https://doi.org/doi: 10.1016/S1470-2045(22)00687-8
Final published version
https://doi.org/10.1016/s1470-2045(22)00687-8
Final published version

Paolo A Ascierto
Daniil Stroyakovskiy
Helen Gogas
Caroline Robert
Karl Lewis
Svetlana Protsenko
Rodrigo P Pereira
Thomas Eigentler
Piotr Rutkowski
Lev Demidov
Natalia Zhukova
Jacob Schachter
Yibing Yan
Ivor Caro
Christian Hertig
Cloris Xue
Lieke Kusters
Grant A McArthur
Ralf Gutzmer

Original language	English
Pages (from-to)	33-44
Journal	The Lancet Oncology
Volume	24
Issue number	1
DOIs	https://doi.org/doi: 10.1016/S1470-2045(22)00687-8 https://doi.org/10.1016/s1470-2045(22)00687-8
State	Published - 1 Jan 2023

ID: 116164561